CEBPA and lip and oral cavity carcinoma: demonstrated that CEBPA-DT overexpression could inhibit IL-17 signaling to induce the release of cytokines and disruption of immune infiltration, which ultimately enhanced cisplatin resistance to chemotherapy in oral cancer (92).